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Abstract 9 
High strain sequence variability, interference with innate immune mechanisms, and epitope 10 
deletion are all examples of strategies that pathogens have evolved to subvert host defenses. To 11 
this list we would add another strategy: immune camouflage. Pathogens whose epitope 12 
sequences are cross-conserved with multiple human proteins at the TCR-facing residues may be 13 
exploiting “ignorance and tolerance”, which are mechanisms by which mature T cells avoid 14 
immune responses to self-antigens. By adopting amino acid configurations that may be 15 
recognized by autologous regulatory T cells, pathogens may be actively suppressing protective 16 
immunity. Using the new JanusMatrix TCR-homology-mapping tool, we have identified several 17 
such ‘camouflaged’ tolerizing epitopes that are present in the viral genomes of pathogens such as 18 
emerging H7N9 influenza. Thus in addition to the overall low number of T helper epitopes that is 19 
present in H7 hemaglutinin (as described previously, see http://dx.doi.org/10.4161/hv.24939), the 20 
presence of such tolerizing epitopes in H7N9 could explain why, in recent vaccine trials, whole 21 
H7N9-HA was poorly immunogenic and associated with low seroconversion rates (see 22 
http://dx.doi.org/10.4161/hv.28135). In this commentary, we provide an overview of the 23 
immunoinformatics process leading to the discovery of tolerizing epitopes in pathogen genomic 24 
sequences, provide a brief summary of laboratory data that validates the discovery, and point the 25 
way forward. Removal of viral, bacterial and parasite tolerizing epitopes may permit researchers 26 
to develop more effective vaccines and immunotherapeutics in the future.  27 
 28 
29 
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Immune Camouflage: Relevance to Vaccine Design and Human Immunology 1 
 2 
Learning from pathogens how to make better vaccines and biologics 3 
Just as humans have evolved immune mechanisms to combat infection, viruses, bacteria, and 4 
parasites have found ways to fight back against human defenses. It appears that the emerging 5 
H7N9 influenza virus is one of several viruses that have learned to evade host defenses. Immune 6 
evasion strategies contribute to pathogen persistence at the population and individual level, 7 
making it difficult to develop effective vaccines. Examples of pathogens for which effective 8 
vaccines are lacking include herpes simplex virus (HSV), human immuno-deficiency virus (HIV), 9 
respiratory syncytial virus (RSV), and cytomegalovirus (CMV) among viruses; M. tuberculosis, H. 10 
pylori, and S. aureus among bacteria; and Leishmania, Trypanosoma, and Filaria species among 11 
parasites. Vaccines developed against H7N9 have also proven to be poorly immunogenic, as 12 
compared to those developed for the most recent pandemic (H1N1), perhaps due to immune 13 
evasion strategies described previously by our group.1,2 14 
 15 
Fortunately, human beings can learn to fight back. Using advanced bioinformatics tools, we are 16 
now able to search pathogen sequences for elements that enable pathogen escape from the 17 
immune system and use this information to improve vaccines. The same approach may also be 18 
used to improve vaccines against cancer antigens (by identifying regions of those antigens that 19 
may be actively tolerizing) and to reduce the immunogenicity of biologic therapeutics (by 20 
introducing or conserving tolerogenic epitopes to promote drug-specific tolerance). Our group 21 
uses an integrated set of bioinformatics tools (iVAX) that have been extensively validated for 22 
antigen sequence analysis and vaccine design3 to identify immunogenic signals encoded in 23 
pathogen genomes; recent papers describing the use of the iVAX toolkit include applications to H. 24 
pylori4 and Hepatitis C.5 25 
 26 
One weapon that we can use to fight back against human pathogens is to design better vaccines. 27 
JanusMatrix is a new tool for analyzing the genomes of pathogens that appears to be capable of 28 
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identifying regulatory T cell (Treg) epitopes. We described the application of this tool to the 1 
emerging H7N9 avian influenza genome in this journal. Our initial immunoinformatics analysis 2 
revealed two potential means by which H7N9 might evade immune response: (1) reduced 3 
numbers of T helper epitopes in the H7N9 hemagglutinin (HA) protein, the primary antigen 4 
against which protective antibody response is focused1 and (2) the presence of T cell epitopes 5 
highly cross-conserved with the human genome.2 Subsequent reports revealed that vaccines 6 
developed using H7N9-HA were indeed poorly immunogenic, as was predicted. Extremely low 7 
seroconversion rates of 6% were observed. 6 , 7  In contrast, the rate of seroconversion to 8 
unadjuvanted monovalent pandemic H1N1 is reported to be 89%.8-10 Perhaps more importantly, 9 
and related to the relative paucity of T helper epitopes, careful analysis of humoral immune 10 
responses to H7N9 revealed that human antibody response to the virus was diminished and 11 
delayed, and the resulting HA-specific antibodies had poor avidity compared to serological 12 
responses to other influenza subtypes.11   13 
 14 
A new mechanism of immune escape: immune camouflage 15 
 16 
More specifically, as will be reviewed here, the JanusMatrix tool has uncovered the ability of 17 
some pathogens to introduce HLA class II sequences (over the course of their co-evolution with 18 
human hosts) that are highly cross-conserved at the T cell receptor (TCR) face with the human 19 
genome12 (Figure 1). This is a new mechanism of subterfuge, and it is deserving of intensive 20 
study, since it may explain why it has been difficult to develop effective vaccines for certain 21 
pathogens using subunit (whole antigen) vaccines. Furthermore, we can leverage this information 22 
by searching pathogen genomes for human homologs: these “human-like” epitopes may play an 23 
important role in the regulation of immune tolerance. 24 
 25 
Maintaining tolerance is an active and constant process that involves regulatory T cells (Tregs), 26 
and reinforcement by the continued presence of antigen may be important.13 Circulating Tregs 27 
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dampen immune responses to self-epitopes displayed on antigen-presenting cells, diminishing 1 
the chance of autoimmunity.  2 
We believe that pathogens may use the same tolerance-inducing Tregs as a means of escaping 3 
immune response. Accordingly, this commentary expands on our previous observations related to 4 
emerging H7N9 in this journal by explaining how JanusMatrix can be used to identify HLA class II 5 
epitopes from pathogen sequences that have identical TCR-facing residues to multiple human 6 
genome epitopes.12 We are now using JanusMatrix for large-scale analyses of viral, bacterial and 7 
parasite sequences for such tolerizing, or Treg epitope (“Tregitope”) signals and validating this 8 
hypothesis in vitro and in vivo. While Tregitopes and tolerizing epitopes may improve biologics,14 9 
they may hinder the effectiveness of subunit vaccines15 in the clinic.    10 
 11 
Established immune escape mechanisms  12 
 13 
Although novel, viral camouflage is not the first mechanism of immune escape to be discovered. 14 
There is an extensive literature on the many ways by which pathogens evade detection, some of 15 
which are described briefly in the following paragraphs. 16 
 17 
a. Defense against innate immunity  18 
Bacteria and viruses are known to interfere with innate immune responses by producing 19 
proteases that degrade host defense factors,16 secreting exact replicates of human cytokines that 20 
suppress immune response,17 cleaving or evading complement activation,18 impeding phagocyte 21 
recruitment,19 interfering with reactive oxygen species,20 escaping neutrophil extracellular traps,21 22 
and generating pore-forming cytolysins,22 among other mechanisms.  23 
 24 
b. Defense against adaptive immune response  25 
Viruses also delete T cell epitopes to evade recognition by human T cells. This process, known 26 
as “deimmunization” in the biologics industry, has been observed in the course of infection by 27 
RNA viruses (HIV, HCV23-25). Evaluations of total T cell epitope content in bacterial genomes 28 
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appear to confirm that deimmunization may also occur in selected bacteria.26 Since viruses have 1 
successfully demonstrated that T cell epitope deletion is a viable immune escape strategy, 2 
deimmunization has been applied to the development of less immunogenic protein therapeutics.27 3 
Importantly, reduction of T cell epitopes is not limited to avoiding immune recognition; it also 4 
results in reduced antibody titers and diminished antibody affinity.11 5 
  6 
c. Treg epitopes or tolerizing epitopes 7 
In 2007, we made the surprising discovery that there were highly conserved, promiscuous T-cell 8 
epitopes located in the Fc region and framework of the Fab region of IgG.28 We hypothesized that 9 
these were regulatory T cell epitopes, which we nicknamed Tregitopes, and later determined that 10 
natural regulatory T cells (nTregs) upregulated FoxP3 following exposure to Tregitopes in vitro, 11 
suppressed bystander immune responses, modified antigen presenting cell phenotype toward a 12 
tolerogenic DC (DCreg29), and that Tregitope treatment in vivo induced adaptive tolerance.30 13 
 14 
One question that frequently came up when we presented our new Tregitope discovery was 15 
whether similar peptides were also found in pathogen genomes. However, we were not able to 16 
search for pathogen Tregitopes until we developed JanusMatrix. This tool made it possible to 17 
begin to search viral, bacterial, and parasite genomes for human homology at the TCR face. For 18 
example, with Bailey-Kellogg and He of Dartmouth, we used JanusMatrix to scan viral genomes 19 
for Tregitopes, and found that chronic or commensal viruses (“hit-and-stay”) that establish 20 
persistent infection in humans are deimmunized and contain more viral Tregitopes than viruses 21 
that “hit-and-run” such as Ebola, Marburg and variola.12  22 
 23 
Identification of tolerizing epitopes in pathogen sequences (and development of tools for defining 24 
them) has important ramifications for the design of vaccines against human pathogens, 25 
particularly those that persist in humans and appear to have adopted this immune defense. The 26 
evolution of this concept and a few case studies are presented in the following sections.  27 
 28 
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Defining Pathogen “Tregitopes”? 1 
 2 
Cross-reactivity is an intrinsic characteristic of the TCR that is widely recognized to be critically 3 
important for the development of thymus-derived T cells, autoimmunity, and heterologous 4 
immunity. To define cross-conserved T cell epitopes, we use JanusMatrix, which operates in 5 
conjunction with an existing T cell epitope-mapping platform (EpiMatrix)31 JanusMatrix harnesses 6 
EpiMatrix to define HLA-binding peptides while searching for cross-conservation at the TCR face 7 
in any protein sequence databases of interest (uploaded and selected by the user). We have 8 
examined TCR-facing residues for conservation against a variety of human sequence databases, 9 
including the complete human proteome, the plasma proteome and the human microbiome. 31 10 
 11 
Preliminary studies appear to corroborate the immune camouflage hypothesis. In collaboration 12 
with Gregory and Losikoff, we discovered a tolerizing epitope in HCV using JanusMatrix.31 13 
Subsequently, we discovered and described epitopes in H7N9 that have similar features 32 14 
(Figure 2).  In the next three sections, we summarize our recent experience with JanusMatrix and 15 
highlight the validation studies that have been performed. These newly defined viral Tregitopes 16 
will be described briefly below.  17 
 18 
a. HCV 19 
Gregory and Losikoff prospectively identified highly human-like and promiscuous HCV T cell 20 
epitopes that were subsequently shown to be Tregitopes in the context of chronic HCV 21 
infection. 33  One particular sequence, which stimulated interferon-gamma production by T 22 
lymphocytes derived from non-HCV-infected patients, induced a significant increase in functional 23 
CD3+CD4+FoxP3+ Tregs among PBMCs derived from young adults who were recently infected 24 
(<5 years) and remained infected with HCV (Losikoff et al. manuscript in preparation34). Other, 25 
less human-like HCV peptides had no effect on Treg cell expansion. Importantly, a human 26 
peptide to which the HCV peptide had identical TCR-facing residues also stimulated a marked 27 
increase in Tregs among PBMCs from non-infected as well as infected individuals. This suggests 28 
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that the HCV genome contains cross-reactive viral epitopes that can suppress Teffector cell 1 
function by promoting Treg cell activity. In fact, it is already well established that HCV-induced 2 
Treg activation is associated with extended chronicity of HCV infection,35 but until now it has been 3 
difficult to define which T cell epitopes engage human Tregs.  4 
 5 
b. Influenza 6 
We previously described H7N9 influenza 2013 as a “stealth” virus, capable of evading human 7 
immune response.1 In addition to the low T cell epitope content and limited conservation with 8 
circulating influenza strains, tolerizing epitopes may be present in H7-HA, contributing to the low 9 
immunogenicity and poor efficacy of the HA-based vaccine.2 Consistent with our previous 10 
analysis of viral genomes,12 we have identified a number of T cell epitopes in H7N9 that are 11 
cross-conserved with other influenza A viruses (IAVs) but also extensively cross-conserved with 12 
human genome. Peptides that are extensively cross-conserved with human genome may have an 13 
immuno-suppressive effect, which could explain why the development of antibodies to H7 HA 14 
appears to be delayed and the antibodies have poor affinity when compared to other antibodies 15 
to other HA proteins in H7N9-infected patients.11 Our in vitro studies of cross-reactive peptides in 16 
H7N9 appear to support the observations made in the case of HCV, described above.32  17 
  18 
c. HIV 19 
We recently applied JanusMatrix to analyzing the HIV genome, rationalizing that RNA viruses 20 
may be alike in their propensity to adopt immune camouflage as a means of escaping immune 21 
response. To our surprise, several epitopes contained in the Env protein appear to be highly 22 
cross-conserved with the human genome. One such epitope is depicted using Cytoscape to 23 
describe its connectedness with other epitopes in the human genome, Figure 3. We are currently 24 
evaluating this epitope, and other epitopes like it, to determine whether these epitopes may 25 
contribute to immune camouflage, in HIV infection. 26 
  27 
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Relevance to Vaccine design 1 
 2 
Conservation with the human genome may be a means by which viruses escape human immune 3 
response. Better classification of viral epitopes as either effector or regulatory will improve the 4 
design of vaccines against pathogens that adopt immune camouflage. Modification of vaccine 5 
immunogens to epitopes that drive viral-specific T cell responses may also improve the efficacy of 6 
these vaccines. Alternatively, one might develop epitope-driven subunit vaccines, either as whole 7 
antigen vaccines, using a structure-based approach, or alternatively, as platform-neutral epitope-8 
based vaccines that do not contain tolerizing epitopes or Tregitopes. Such vaccines may have 9 
major advantages over conventional approaches, as they simultaneously account for viral and 10 
human diversity for broad reactivity and drive protective viral-specific T cell responses. For 11 
instance, the low immunogenicity of H7N9 might be overcome by introducing into the vaccine T 12 
cell epitopes cross-conserved with seasonal influenza A strains and removing vaccine epitopes 13 
cross-conserved with human proteins, which may promote down-regulation of protective 14 
inflammatory responses. 15 
 16 
Relevance to biologics design 17 
Whereas immunogenicity is considered to be a positive attribute for vaccines, immunogenicity 18 
that occurs in the course of treatment with biologic therapies is a topic of some concern to 19 
biologics developers. While there are many factors that contribute to protein immunogenicity, T 20 
cell-driven (Td) responses appear to play a critical role in the development of antibody responses 21 
to biologic therapeutics. A range of methodologies to predict and mitigate Td immune responses 22 
to protein drugs has been developed. Perhaps integrating Tregitopes into protein therapeutics will 23 
reduce their immunogenicity.14 We also plan to scan protein therapeutics for pre-existing 24 
Tregitopes; our deimmunization programs would leave Tregitopes intact while removing other, 25 
more immunogenic T cell epitopes.  26 
 27 
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Conclusion 1 
 2 
The implication of the studies emerging from the exploration of the “two-faced” T cell epitope with 3 
the JanusMatrix tool is that TCR cross-reactivity at the level of the human genome is potentially 4 
linked to a Treg phenotype of human T cell responses to pathogens. The implications for vaccine 5 
developers should be clear: remove such epitopes from vaccine antigens. The implications for 6 
biologics developers may be more nuanced but are equally important – prioritization of T cell 7 
epitopes for removal may depend on the degree of cross-conservation with self, even if the 8 
protein is autologous in origin.  9 
 10 
In addition, TCR cross-reactivity may play a role in autoimmune disease through a concept 11 
known as molecular mimicry.36 Applications of JanusMatrix may be relevant, therefore, in the 12 
context of autoimmune diseases following vaccination, such as Guillain-Barre syndrome or 13 
Narcolepsy.37-39  14 
 15 
Finally, pathogen subterfuge may teach us something about our own immune system. What is the 16 
role of human peptide epitopes that are themselves cross-reactive with other human sequences? 17 
Are these Tregitopes serving an important purpose, reinforcing tolerance to proteins that are 18 
critically important for human survival? Pathogens may have exploited an immune tolerance 19 
mechanism that we were completely unaware of until now. 20 
 21 
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Figure Legends 1 
 2 
Figure 1. Cross-conservation between T-cell receptor facing residues of T cell epitopes 3 
may influence immune response. Pathogens may exploit cross-conservation with self to reduce 4 
immune recognition of pathogen epitopes. Cross-reactivity with the human microbiome has also 5 
been observed. The sum or ratio of these influences may determine the phenotype of the 6 
responding T cells. Understanding cross-conservation of the T cell epitope and its context is 7 
critically important for understanding human immune responses to infection and vaccination. 8 
 9 
Figure 2. Cross-conservation between T-cell receptor facing residues of T cell epitopes 10 
and the human genome may influence the response to influenza H7N9. The virus may 11 
exploit cross-conservation between its own epitopes with self epitopes (top). Unique epitopes 12 
(middle) may be diminished, as has been demonstrated in our previous report. Cross-reactivity 13 
with other influenza A strains may also be present (bottom), further modifying the immune 14 
response. Each of these influences contributes to the final response to influenza infection or 15 
vaccination, including seroconversion rates and antibody maturation and affinity.  16 
 17 
Figure 3.  Putative Tolerizing T cell epitopes found in HIV. Cytoscape can be used to illustrate 18 
the relationship between a pathogen epitope and the human genome. In this figure the source 19 
HIV Env peptide is represented as a green diamond, its constituent nine-mer epitopes as gray 20 
squares, its cross-conserved partners in the human genome as blue triangles, and the source 21 
human proteins as light purple circles. As shown in this figure, not only is the Env peptide highly 22 
conserved in a number of different human proteins, but a single cross-conserved epitope can be 23 
found in 32 alleles of the same human protein (source protein highlighted in orange). 24 
 25 
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A.  Original peptide (from HIV-1 Env) 
B.  Nine-mer frame of HIV peptide predicted to bind HLA 
C.  Human nine-mer with identical TCR contact residues 
D.  Source protein of human nine-mer 
